Boston Scientific Corp
Research Boston Scientific Corp (BSX) on Bullrun: valuation model: 25.5% undervalued, market cap USD 64.63B, P/E 18.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBSX
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal25.5% undervalued
- Market capUSD 64.63B
- P/E18.2
- Financial periodFY2025
- RevenueUSD 20.07B
- Revenue growth19.9%
- Net incomeUSD 2.89B
- Free cash flowUSD 3.66B
- Gross margin69.0%
Valuation Snapshot
Bullrun's latest valuation model marks Boston Scientific Corp as 25.5% undervalued; latest market cap is USD 64.63B; P/E is 18.2.
About Boston Scientific Corp
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Frequently asked questions
Is Boston Scientific Corp overvalued or undervalued?
Bullrun's valuation model currently marks Boston Scientific Corp as 25.5% undervalued.
What is Boston Scientific Corp's market cap?
Boston Scientific Corp's market capitalization is USD 64.63B.
What is Boston Scientific Corp's P/E ratio?
Boston Scientific Corp's price-to-earnings (P/E) ratio is 18.2.
What does Boston Scientific Corp do?
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.